Steven Pieper - 05 Mar 2026 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Reporting relationship: Chief Financial Officer
Issuer ticker: XERS
Reported as of: 05 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Mar 2026, 19:18:28 UTC
Prior SEC filing: 02 Feb 2026
Next SEC filing: 07 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Beth Hecht, Attorney-in-Fact

Key filing fact

Steven Pieper filed Form 4 for Xeris Biopharma Holdings, Inc. (XERS) on 05 Mar 2026.

Key facts

This page summarizes Steven Pieper's Form 4 filing for Xeris Biopharma Holdings, Inc. (XERS).
4 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 05 Mar 2026, 19:18.

Change

Previous filing in this sequence was filed on 02 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001875714 Primary reporting owner

Pieper Steven

Relationship: Chief Financial Officer
Address: C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO
Signature: /s/ Beth Hecht, Attorney-in-Fact
Signature date: 05 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XERS transaction

Common Stock

Options Exercise

Transaction value
Shares: +27,891
Change %: +2%
Price: $4.09^*
Shares after: 1,394,904
Date: 05 Mar 2026
Ownership: Direct

XERS transaction

Common Stock

Options Exercise

Transaction value
Shares: +14,036
Change %: +1%
Price: $5.93^*
Shares after: 1,408,940
Date: 05 Mar 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

XERS transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -27,891
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 05 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 27,891
Exercise price: $4.09
Footnotes: F1

XERS transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -14,036
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 05 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 14,036
Exercise price: $5.93
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The reporting person received the stock options on December 10, 2020 pursuant to an award under the Company's 2018 Stock Option/Stock Issuance Plan. 50% of the options vested on the first anniversary of the vesting commencement date, and the remaining 50% of options vested on the second anniversary of the vesting commencement date, in each case subject to continued employment through such vesting date.

Footnote F2

The reporting person received the stock options on January 31, 2018 pursuant to an award under the Company's 2011 Stock Option/Stock Issuance Plan. 25% of the options vested on the first anniversary of the vesting commencement date, and the remaining 75% of options vested in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date.

SEC remarks

Chief Financial Officer